Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Apr;21(4):371–376. doi: 10.1111/j.1365-2125.1986.tb05209.x

Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects.

I D Bradbrook, M Babiker, P Crome, H C Gillies, P J Morrison, H J Rogers, P Shotton
PMCID: PMC1400951  PMID: 3707811

Abstract

Oxprenolol in an Oros 8/130 sustained release osmotic pump system (equivalent to 120 mg oxprenolol hydrochloride in a conventional formulation and releasing 8 mg h-1) was given to eight normal young subjects (mean age 23 years) and eight elderly hypertensive patients (mean age 77 years). The plasma concentration-time profiles of oxprenolol were determined over 32 h using gas liquid chromatography after the initial dose and following seven doses. The elderly patients had a significantly higher AUC and maximum plasma oxprenolol concentration following both the first and final doses studied. It is unlikely that this difference is due to a prolonged absorption phase in the elderly patients. Reduced drug clearance seems the most probable explanation.

Full text

PDF
371

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barber H. E., Hawksworth G. M., Kitteringham N. R., Petersen J., Petrie J. C., Swann J. M. Protein binding of atenolol and propranolol to human serum albumin and in human plasma [proceedings]. Br J Clin Pharmacol. 1978 Nov;6(5):446P–447P. [PubMed] [Google Scholar]
  2. Belpaire F. M., Bogaert M. G., Rosseneu M. Binding of beta-adrenoceptor blocking drugs to human serum albumin, to alpha 1-acid glycoprotein and to human serum. Eur J Clin Pharmacol. 1982;22(3):253–256. doi: 10.1007/BF00545224. [DOI] [PubMed] [Google Scholar]
  3. Castleden C. M., George C. F. The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol. 1979 Jan;7(1):49–54. doi: 10.1111/j.1365-2125.1979.tb00896.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hitzenberger G., Fitscha P., Beveridge T., Nüesch E., Pacha W. Effects of age and smoking on the pharmacokinetics of pindolol and propranolol. Br J Clin Pharmacol. 1982;13(Suppl 2):217S–222S. doi: 10.1111/j.1365-2125.1982.tb01914.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hurwitz N. Predisposing factors in adverse reactions to drugs. Br Med J. 1969 Mar 1;1(5643):536–539. doi: 10.1136/bmj.1.5643.536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kendall M. J., Quarterman C. P., Bishop H., Schneider R. E. Effects of inflammatory disease on plasma oxprenolol concentrations. Br Med J. 1979 Aug 25;2(6188):465–468. doi: 10.1136/bmj.2.6188.465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kendall M. J., Quarterman C. P. The effect of age on the pharmacokinetics of oxprenolol. Int J Clin Pharmacol Ther Toxicol. 1982 Mar;20(3):101–104. [PubMed] [Google Scholar]
  9. Lennard M. S., Silas J. H., Smith A. J., Tucker G. T. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr. 1977 Mar 11;133(1):161–166. doi: 10.1016/s0021-9673(00)89216-x. [DOI] [PubMed] [Google Scholar]
  10. Mason W. D., Winer N. Pharmacokinetics of oxprenolol in normal subjects. Clin Pharmacol Ther. 1976 Oct;20(4):401–412. doi: 10.1002/cpt1976204401. [DOI] [PubMed] [Google Scholar]
  11. Quarterman C. P., Kendall M. J., Jack D. B. The effect of age on the pharmacokinetics of metoprolol and its metabolites. Br J Clin Pharmacol. 1981 Mar;11(3):287–294. doi: 10.1111/j.1365-2125.1981.tb00536.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Rigby J. W., Scott A. K., Hawksworth G. M., Petrie J. C. A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects. Br J Clin Pharmacol. 1985 Oct;20(4):327–331. doi: 10.1111/j.1365-2125.1985.tb05072.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Roux A., Henry J. F., Fouache Y., Chau N. P., Hervy M. P., Forette F., Bourdarias J. P., Flouvat B. A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. Gerontology. 1983;29(3):202–208. doi: 10.1159/000213115. [DOI] [PubMed] [Google Scholar]
  14. Schneider R. E., Bishop H., Yates R. A., Quarterman C. P., Kendall M. J. Effect of age on plasma propranolol levels. Br J Clin Pharmacol. 1980 Aug;10(2):169–171. doi: 10.1111/j.1365-2125.1980.tb01736.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sioufi A., Colussi D., Mangoni P. Gas chromatographic determination of oxprenolol in human plasma. J Chromatogr. 1983 Nov 11;278(1):185–188. doi: 10.1016/s0378-4347(00)84772-6. [DOI] [PubMed] [Google Scholar]
  16. Theeuwes F. Elementary osmotic pump. J Pharm Sci. 1975 Dec;64(12):1987–1991. doi: 10.1002/jps.2600641218. [DOI] [PubMed] [Google Scholar]
  17. Vestal R. E., Wood A. J., Branch R. A., Shand D. G., Wilkinson G. R. Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther. 1979 Jul;26(1):8–15. doi: 10.1002/cpt19792618. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES